Do you want to read an article? Please log in or register.
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
Heart Failure
Related content
Heart Failure
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial
JACC Heart Fail.
McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, Lewsey JD, Krum H; VIVIDD Trial Committees and Investigators
doi: 10.1016/j.jchf.2017.08.004.
Atrial FibrillationHeart Failure
Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation
Eur J Heart Fail.
Polovina M, Lund LH, Đikić D, Petrović-Đorđević I, Krljanac G, Milinković I, Veljić I, Piepoli MF, Rosano GMC, Ristić AD, Ašanin M, Seferović PM
doi: 10.1002/ejhf.1666.
Heart FailureFurther Publications
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (met-HeFT)
Am Heart J
Wiggers H, Køber L, Gislason G, Schou M, Poulsen MK, Vraa S, Nielsen OW, Bruun NE, Nørrelund H, Hollingdal M, Barasa A, Bøttcher M, Dodt K, Hansen VB, Nielsen G, Knudsen AS, Lomholdt J, Mikkelsen KV, Jonczy B, Brønnum-Schou J, Poenaru MP, Abdulla J, Raymond I, Mahboubi K, Sillesen K, Serup-Hansen K, Madsen JS, Kristensen SL, Larsen AH, Bøtker HE, Torp-Petersen C, Eiskjær H, Møller J, Hassager C, Steffensen FH, Bibby BM, Refsgaard J, Høfsten DE, Mellemkjær S, Gustafsson F
doi: 10.1016/j.ahj.2020.09.020
Heart Failure
Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial
Cardiovasc Diabetol
Kusunose K, Imai T, Tanaka A, Dohi K, Shiina K, Yamada T, Kida K, Eguchi K, Teragawa H, Takeishi Y, Ohte N, Yamada H, Sata M, Node K, CANDLE Trial Investigators.
doi: 10.1186/s12933-021-01380-w
Heart FailureMyocardial Infarction
Contrasting Associations of Body Mass Index and Hemoglobin A1c on the Excess Risk of Acute Myocardial Infarction and Heart Failure in Type 2 Diabetes Mellitus
J Am Heart Assoc.
Edqvist J, Rawshani A, Adiels M, Björck L, Lind M, Svensson AM, Gudbjörnsdottir S, Sattar N, Rosengren A
doi: 10.1161/JAHA.119.013871.
Heart Failure
Use of Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure and Type 2 Diabetes Mellitus: Data from the Swedish Heart Failure Registry
Eur J Heart Fail
Becher PM, Schrage B, Ferrannini G, Benson L, Butler J, Carrero JJ, Cosentino F, Dahlström U, Mellbin L, Rosano GM, Sinagra G, Stolfo D, Lund LH, Savarese G
doi: 10.1002/ejhf.2131
RECOMMENDED
Cardiovascular Risk and Diseases
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc.
Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B
doi: 10.1161/JAHA.119.014908.
Heart Failure
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS
Am Heart J.
Bhatt AS, Luo N, Solomon N, Pagidipati NJ, Ambrosio G, Green JB, McGuire DK, Standl E, Cornel JH, Halvorsen S, Lopes RD, White HD, Holman RR, Peterson ED, Mentz RJ, TECOS Study Group.
doi: 10.1016/j.ahj.2019.08.016.
Heart Failure
Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial
J Am Heart Assoc.
Sharma A, Vaduganathan M, Ferreira JP, Liu Y, Bakris GL, Cannon CP, White WB, Zannad F
doi: 10.1161/JAHA.119.012797.